Pre-close Trading Update

RNS Number : 6418Y

Alliance Pharma PLC

09 July 2008

 



For immediate release

9 July 2008

ALLIANCE PHARMA PLC

('Alliance Pharma' or 'the Company')

Pre-close Trading Update

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces a pre-close trading update ahead of the announcement of its interim results for the six months ended 30 June 2008.

Trading is in line with expectations with half year sales expected to be in the region of £9.9 million, a 27% increase on the first half last year, which in part reflects the resolution of third party supply issues.

As a result, profit before tax for the half year is expected to be in the region of £1.0 million, demonstrating the continuing success of the steps initiated last year to substantially improve profitability. Additionally, post-tax profit is likely to be enhanced by potential R&D tax credits announced on 1 July 2008.

The Company's interim results are due to be announced on 10 September 2008.

For further information: 

Alliance Pharma plc	+ 44 (0) 1249 466966
John Dawson, Chief Executive
Richard Wright, Finance Director
www.alliancepharma.co.uk
Buchanan Communications	+ 44 (0) 20 7466 5000
Mark Court / Rebecca Skye Dietrich
Numis Securities Limited	+ 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Brent Nabbs
Corporate Broking: David Poutney

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

TSTSSSSIUSASEDW